Table 2.
Active combinatorial trials in breast cancer.
| Trial ID | Cancer | PARP inhibitor | Immunotherapy | Phase |
|---|---|---|---|---|
| NCT03101280 | TNBC | Rucaparib | Atezolizumab (PD-1) | I |
| NCT03544125 | Metastatic TNBC | Olaparib | Durvalumab (PD-1) | I |
| NCT02660034 | TNBC | BGB-290 | BGB-A317 (PD-1) | I/II |
| NCT02484404 | TNBC | Olaparib | Atezolizumab (PD-L1) cediranib (VEGFR) | I/II |
| NCT02657889 | TNBC | Niraparib | Pembrolizumab (PD-1) | I/II |
| NCT02734004 | Breast Cancer | Olaparib | Durvalumab (PD-L1) +/- bevacizumab | I/II |
| NCT02849496 | TNBC, stage III/IV | Olaparib | Atezolizumab (PD-L1) | II |
| NCT03167619 | Advanced, platinum treated TNBC | Olaparib | Durvalumab (PD-1) | II |
| NCT03330405 | TNBC | Talazoparib | Avelumab (PD-1) | II |
| NCT03740893 | Advanced TNBC | Olaparib | Durvalumab (PD-1) | II |
| NCT03801369 | Metastatic TNBC | Olaparib | Durvalumab (PD-1) | II |
TNBC, triple-negative breast cancer.